资讯

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China ...
Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase ...
Pharmaceutical Technology on MSN10 小时
Redwire gains Aspera contract for space-based cancer research
Space infrastructure company Redwire Corporation has secured a contract from Aspera Biomedicines to carry out space-based ...
Sagimet Biosciences shares soar on positive acne treatment trial results
In light of the promising results, Ascletis is planning to seek approval for denifanstat from the China National Medical Products Administration. Moreover, Sagimet has initiated a Phase 1 clinical ...
Sagimet Biosciences Announces Positive Phase 3 Results For Denifanstat For The Treatment Of ...
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel ...
InvestorsHub on MSN16 小时
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results
Sagimet Biosciences Inc. (NASDAQ:SGMT) saw its stock soar 20% after unveiling encouraging Phase 3 trial results for its acne ...